5 research outputs found

    <span style="font-size:15.0pt;mso-bidi-font-size: 14.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman"; mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA" lang="EN-US">Analysis of phytochemical, antimicrobial, and antioxidant properties of <i style="mso-bidi-font-style:normal">Sarcandra glabra </i><span style="mso-bidi-font-style:italic">(Thunb.) Nakai in relation to its ethnomedicinal relevance in Cordillera, Philippines</span></span>

    No full text
    411-416Sarcandra glabra (Thunb.) Nakai, one of the ethnomedicinal plants used by the Cordillerans, is believed to treat various ailments based from the existing ethnoknowledge of Kalanguya tribe. However, scientific recognition of its claimed clinical consequences is limited. Hence, this research aims to identify its bioactive compounds as well as its antimicrobial and free radical scavenging activity which may be used to evaluate its potency. Standard tests for evaluating different bioactive compounds were employed for the identification of present phytochemicals. Results showed the presence of carbohydrates, phytosterols mainly diterpenes and triterpenes, phenolic compounds, flavonoids and proteins. In the assessment of its antimicrobial potential against Escherichia coli and Staphylococcus aureus, Kirby-Bauer Disc Diffusion method was employed; and the extract demonstrated negative inhibition against these bacteria. 2,2-diphenyl-1-picrylhydrazyl (DPPH) method was executed for the detection of its antioxidant property, and the result showed that S. glabra has a free radical scavenging activity indicated by a decrease in the absorption of DPPH as the concentration of the extract increases. Findings indirectly suggest the therapeutic assertions potentiality of the ethnomedicinal plant. Therefore, clinical therapeutic trials are recommended to confirm therapeutic claims.</span

    Free Radical Scavenging and In vitro Cytotoxic Activity of Bugnay (Antidesma bunius) Leaves Extract against A549 Human Lung Adenocarcinoma and HCT-116 Human Colorectal Cancer Cell Lines

    No full text
    Cancer is one of the significant causes of mortality worldwide. Studies on antineoplastic drugs focused on natural products have revealed several mechanisms to inhibit cancer cells. Bugnay (Antidesma bunius) leaves showed potentials due to its activity observed against brine shrimp and breast cancer cells. However, there is still limited knowledge about its activity against other human cancer cells. This study focused on determining the phytochemical compounds in A. bunius leaves extract, the free radical scavenging activity of the extract using the Diphenylpicrylhydrazyl (DPPH) method, and in vitro cytotoxic activity against two cancer cell lines, namely HCT-116 human colorectal and A549 human lung adenocarcinoma cancer cell lines by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The phytochemicals identified were unsaturated lactones, flavonoids, phenolics, diterpenes, saponins, tannins, carbohydrates, and reducing sugars. The extract showed significant free radical scavenging activity and a direct correlation of activity with concentration levels. It also exhibited cytotoxic activity against HCT-116 human colorectal and A549 human lung adenocarcinoma. Hence, A. bunius leaves have the potential to be a source of antioxidant and antineoplastic compounds. This warrant further isolation of the compounds for chemotherapeutic purposes.Keywords: Antidesma bunius, Bugnay, Cancer, Cytotoxicity, Radica

    The ATLAS experiment at the CERN Large Hadron Collider: a description of the detector configuration for Run 3

    Get PDF
    Abstract The ATLAS detector is installed in its experimental cavern at Point 1 of the CERN Large Hadron Collider. During Run 2 of the LHC, a luminosity of  ℒ = 2 × 1034 cm-2 s-1 was routinely achieved at the start of fills, twice the design luminosity. For Run 3, accelerator improvements, notably luminosity levelling, allow sustained running at an instantaneous luminosity of  ℒ = 2 × 1034 cm-2 s-1, with an average of up to 60 interactions per bunch crossing. The ATLAS detector has been upgraded to recover Run 1 single-lepton trigger thresholds while operating comfortably under Run 3 sustained pileup conditions. A fourth pixel layer 3.3 cm from the beam axis was added before Run 2 to improve vertex reconstruction and b-tagging performance. New Liquid Argon Calorimeter digital trigger electronics, with corresponding upgrades to the Trigger and Data Acquisition system, take advantage of a factor of 10 finer granularity to improve triggering on electrons, photons, taus, and hadronic signatures through increased pileup rejection. The inner muon endcap wheels were replaced by New Small Wheels with Micromegas and small-strip Thin Gap Chamber detectors, providing both precision tracking and Level-1 Muon trigger functionality. Trigger coverage of the inner barrel muon layer near one endcap region was augmented with modules integrating new thin-gap resistive plate chambers and smaller-diameter drift-tube chambers. Tile Calorimeter scintillation counters were added to improve electron energy resolution and background rejection. Upgrades to Minimum Bias Trigger Scintillators and Forward Detectors improve luminosity monitoring and enable total proton-proton cross section, diffractive physics, and heavy ion measurements. These upgrades are all compatible with operation in the much harsher environment anticipated after the High-Luminosity upgrade of the LHC and are the first steps towards preparing ATLAS for the High-Luminosity upgrade of the LHC. This paper describes the Run 3 configuration of the ATLAS detector.</jats:p
    corecore